Thomas Weisel

Analysts at Thomas Weisel downgrade Walgreen Company (NYSE: WAG) from "overweight" to "market weight." WAG’s shares soared 0.44% to close at $29.96 yesterday. More Analyst Ratings here

Analysts at Thomas Weisel upgrade RightNow (NASDAQ: RNOW) from "market weight" to "overweight." The target price for RNOW is set to $24. RNOW’s shares fell 0.34% to close at $14.55 on Friday. More Analyst Ratings here

Shares of Deckers Outdoor Corp. (NASDAQ: DECK) are higher on the session by 4.32%, currently trading $144.95. The stock has been a relative outperformer as of late and has managed to hold the 50-day moving average as well, which is a bullish sign. Deckers announced a three-for-one stock split this...

Analysts at Thomas Weisel downgrade DreamWorks Animation SKG Inc (NASDAQ: DWA) from "overweight" to "market weight." The target price for DWA has been reduced from $44 to $38. DWA’s shares fell 1,55% to close at $36.27 yesterday. More Analyst Ratings here

Shares of Fuel System Services Inc. (NASDAQ: FSYS) are moving higher today by 3.71% to $29.38 and are making a run at the 50-day and 200-day moving averages from the downside. While a bullish signal has not been triggered yet, the chart appears to be gaining momentum after basing around the $26...

Analysts at Thomas Weisel initiate coverage of MercadoLibre (NASDAQ: MELI) with an "overweight" rating. Shares of MELI closed at $50.14 yesterday. More Analyst Ratings here.

Analyst Stephen Willey of Thomas Weisel maintains his "market weight" rating on Onyx Pharmaceuticals (NASDAQ: ONXX). The 12-month target price for ONXX is set to $29. According to Thomas Weisel, an exploratory open-label trial (BATTLE) “could generate a positive tailwind for ONXX shares in the near...

Analysts at Thomas Weisel maintain their "overweight" rating on Apple (NASDAQ: AAPL). The target price for AAPL has been raised from $280 to $300. Shares of AAPL closed at $92.00 yesterday. More Analyst Ratings here.

Analysts at Thomas Weisel upgrade CF Industries (NYSE: CF) from “market weight” to “overweight.” Shares of CF rose 0.50% to $90.45 during the pre-market session. More Analyst Ratings here.

Analyst Stephen Willey of Thomas Weisel maintains his "overweight" rating on Anadys Pharmaceuticals Inc (NASDAQ: ANDS). The 12-month target price for ANDS is set to $7. According to Thomas Weisel, “There had been some investor concern around the high placebo response rate observed in the placebo...